We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





First-of-Its-Kind SARS-CoV-2 Antibody Testing System Tests Both Anti-Nucleocapsid and Anti-Spike Antibodies in One Reaction

By LabMedica International staff writers
Posted on 04 Oct 2021

A new high-throughput SARS-CoV-2 antibody testing system could become the only platform capable of testing both anti-nucleocapsid and anti-spike antibodies in one reaction.

SCIENION (Berlin, Germany) has entered into a strategic collaboration with Pictor Limited (Auckland, New Zealand) to commercialize the new high throughput SARS-CoV-2 antibody testing system. The two companies will incorporate SCIENION’s CL2 sciREADER system into Pictor’s PictArray SARS-CoV-2 Serology Test to create the only platform capable of testing both anti-nucleocapsid and anti-spike antibodies in one reaction. This analysis will be key to support the sustained fight against COVID-19 by measuring a population’s level of herd immunity through natural infections and vaccinations.

The combined system will provide a highly automated miniaturized multiplex immunoassay test in a 96 well plate format capable of providing quick analysis on patients’ level of antibodies. The system also leverages proprietary software, developed by Pictor, which produces a risk score for individuals to determine their likelihood of carrying a COVID-19 infection. The PictArray SARS-CoV-2 Serology Test is slated to soon enter clinical trials with the goal of receiving FDA emergency use authorization (EUA) and brought to market in early 2022. The companies also plan to pursue a positive Committee for Medicinal Products for Human Use (CHMP) opinion for use in the UK and EU.

“As COVID-19 remains a widespread concern, measuring antibody levels across populations will be critical for public health officials to stop new variant surges,” said Holger Eickhoff Ph.D., co-founder and CEO of SCIENION GmbH. “We’re honored to work with Pictor to help further develop this vital technology.”

“We are thrilled to have entered into this strategic collaboration with SCIENION,” said Pictor CEO Thomas Schlumpberger. “Leveraging the sciREADER colormetric high performance and accuracy enables Pictor to bring high throughput, high performance and low-cost multiplexed antibody testing for SARS-CoV-2 to the market. We are eager to provide insights into the epidemiological spread of the virus to help inform control and prevention measures.”

Related Links:
SCIENION 
Pictor Limited 

Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nucleic Acid Isolation Kit
MagMAX™ Viral/Pathogen Ultra Nucleic Acid Isolation Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.